Data / Drug companies / Asclemed USA, Inc.
Asclemed USA, Inc.: 686 products in the FDA NDC directory, labeler code 76420
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Asclemed USA, Inc. (labeler code 76420) lists 686 products in the FDA National Drug Code Directory, covering 179 finished drugs by generic name. By type: 613 prescription drugs, 38 bulk ingredients. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 25, 2026.
The request: Watch Asclemed USA, Inc. (FDA labeler code 76420): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 76420
- Products in commercial distribution
- 686
- Packages
- 2,557
- Finished drugs by generic name
- 179
- Prescription products
- 613
- Over the counter products
- 22
- Controlled substance products
- Schedule II 25, Schedule III 16, Schedule IV 55, Schedule V 16
- Flagged as original packager
- 49 of 49 products that carry the flag
- Started marketing in the last 12 months
- 1
- Earliest marketing start
- May 28, 1959
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 533 | 77.7% |
| Other unapproved drugs | 55 | 8% |
| Bulk ingredients for compounding | 35 | 5.1% |
| Authorized generics (NDA) | 19 | 2.8% |
| Over the counter monograph drugs | 15 | 2.2% |
| New drug applications (NDA) | 13 | 1.9% |
| Drugs for further processing | 13 | 1.9% |
| Bulk ingredients | 3 | 0.4% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 613 | 89.4% |
| Bulk ingredients | 38 | 5.5% |
| Over the counter drugs | 22 | 3.2% |
| Drugs for further processing | 13 | 1.9% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 180 | 26.2% |
| Tablet, film coated | 110 | 16% |
| Capsule | 106 | 15.5% |
| Kit | 51 | 7.4% |
| Injection, solution | 34 | 5% |
| Powder | 33 | 4.8% |
| Tablet, extended release | 16 | 2.3% |
| Solution | 14 | 2% |
| Tablet, delayed release | 14 | 2% |
| Cream | 13 | 1.9% |
| Tablet, coated | 10 | 1.5% |
| Capsule, delayed release | 10 | 1.5% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Physicians EZ Use M-pred | 76420-216 | Kit | Other unapproved drugs | September 25, 2026 |
| Xiclo | 76420-332 | Patch | Other unapproved drugs | June 7, 2025 |
| Olu Pain Management | 76420-956 | Patch | Over the counter monograph drugs | April 1, 2025 |
| Aluroderm Scar | 76420-955 | Patch | Over the counter monograph drugs | April 1, 2025 |
| BL-C Kit | 76420-892 | Kit | Other unapproved drugs | December 31, 2024 |
| Ibuprofen | 76420-415 | Tablet | Generic drugs (ANDA) | December 1, 2024 |
| Naloxone Hydrochloride | 76420-867 | Spray, metered | Generic drugs (ANDA) | September 23, 2024 |
| BLT-25 Kit | 76420-851 | Kit | Other unapproved drugs | September 11, 2024 |
| Oxycodone Hydrochloride | 76420-366 | Tablet | Generic drugs (ANDA) | September 10, 2024 |
| Oxycodone Hydrochloride | 76420-365 | Tablet | Generic drugs (ANDA) | September 10, 2024 |
| Oxycodone Hydrochloride | 76420-364 | Tablet | Generic drugs (ANDA) | September 10, 2024 |
| Oxycodone Hydrochloride | 76420-363 | Tablet | Generic drugs (ANDA) | September 10, 2024 |
| Oxycodone Hydrochloride | 76420-362 | Tablet | Generic drugs (ANDA) | September 10, 2024 |
| Promethazine Hydrochloride and Dextromethorphan Hydrobromide | 76420-335 | Solution | Authorized generics (NDA) | September 5, 2024 |
| Ibuprofen | 76420-848 | Tablet, film coated | Generic drugs (ANDA) | May 23, 2024 |
| Ibuprofen | 76420-847 | Tablet, film coated | Generic drugs (ANDA) | May 23, 2024 |
| Ibuprofen | 76420-846 | Tablet, film coated | Generic drugs (ANDA) | May 23, 2024 |
| Baclofen | 76420-358 | Tablet | Generic drugs (ANDA) | February 5, 2024 |
| Diazepam | 76420-316 | Tablet | Generic drugs (ANDA) | December 14, 2023 |
| Diazepam | 76420-315 | Tablet | Generic drugs (ANDA) | December 14, 2023 |
| Diazepam | 76420-314 | Tablet | Generic drugs (ANDA) | December 14, 2023 |
| Tramadol Hydrochloride | 76420-732 | Tablet, coated | Generic drugs (ANDA) | November 28, 2023 |
| Nortriptyline Hydrochloride | 76420-913 | Capsule | Generic drugs (ANDA) | November 17, 2023 |
| Nortriptyline Hydrochloride | 76420-912 | Capsule | Generic drugs (ANDA) | November 17, 2023 |
| Nortriptyline Hydrochloride | 76420-911 | Capsule | Generic drugs (ANDA) | November 17, 2023 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.